Andrew Plump, M.D., Ph.D.
Andrew Plump, M.D., Ph.D., is the Chief Medical and Scientific Officer of Takeda Pharmaceutical and serves as a member of the company’s Board of Directors. His career spans nearly 30 years in the pharmaceutical industry and academia and his experience encompasses early research through regulatory approval and patient access. Dr. Plump’s approach toward drug research and development is reflected in a virtuous cycle of “bench to bedside to bench” learning. He is a true translational physician-scientist, with deep knowledge in biomedical research, experimental medicine, early development, genomics and biomarkers and a history of scientific contributions in neuroscience, cardiovascular and metabolic diseases
Throughout his career, Dr. Plump has been motivated to make an impact for patients by translating groundbreaking science into the practice of healthcare. He is regarded as a multi-dimensional leader who is passionate about leading diverse, cross-functional teams and nurturing a high-performing culture to achieve a shared mission, innovate for patients and change health for the better.
Currently, Dr. Plump leads a modern, world-class R&D organization focused on three therapeutic areas: gastroenterology, neuroscience and oncology, plus vaccines. Through the application of novel modalities and a rich partner ecosystem, the Takeda R&D organization is committed to delivering innovative solutions that address unmet needs.
Prior to Takeda, Dr. Plump served as Senior Vice President, Research & Translational Medicine, Deputy to the President of R&D at Sanofi, based in Paris, France. Prior to Sanofi, Dr. Plump served as Vice President, Worldwide Cardiovascular (CV) Research Head at Merck, where he had direct responsibility for CV research, preclinical development and translational sciences.
Dr. Plump received his M.D. from the University of California, San Francisco (UCSF), his Ph.D. in cardiovascular genetics with Dr. Jan Breslow at Rockefeller University and his B.S. from the Massachusetts Institute of Technology (MIT). He completed a residency in Internal Medicine and a fellowship in Medical Genetics at UCSF. Following his clinical training, Dr. Plump trained as a Howard Hughes and Stanley J. Sarnoff postdoctoral fellow with Dr. Marc Tessier-Lavigne at UCSF, concurrently assuming faculty responsibilities as an Adjunct Clinical Instructor in the Department of Medical Genetics.
Dr. Plump serves on several committees and external boards for organizations including The Sarnoff Cardiovascular Research Foundation, The University of Bristol Integrative Epidemiology Unit, the PhRMA Foundation and the Boston Symphony Orchestra Board of Overseers. In 2018, he received the inaugural UCSF Campaign Alumni Innovator Award and was recognized by Gilda’s Club New York City with the Advances in Cancer Research Award. In 2017, Dr. Plump was invited to deliver the prestigious Daniel I.C. Wang Lecture on the Frontiers of Biotechnology at MIT.